Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...
GlobalData on MSN8h
FDA approves Syndax’s Revuforj to treat leukaemiaThe US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating relapsed or ...
Syndax Pharmaceuticals (SNDX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kelly ...
Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Syndax Pharmaceuticals (SNDX – Research Report). The associated ...
The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...
Syndax Pharmaceuticals (NASDAQ:SNDX) just reported positive results from the phase 2 portion of its AUGMENT-101m trial evaluating the use of Revumenib for the treatment of patients with relapsed ...
WALTHAM, Mass., Nov. 12, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today ...
Also Read: FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication Among the patients who achieved CR/CRh, 12 had a CR, and three had a CRh.
On Wednesday, Goldman Sachs (NYSE:GS) updated its outlook on Syndax Pharmaceuticals (NASDAQ:SNDX), reducing the price target to $31 from the previous $33 while maintaining a Buy rating. The adjustment ...
On Wednesday, Goldman Sachs updated its outlook on Syndax Pharmaceuticals (NASDAQ:SNDX), reducing the price target to $31 from the previous $33 while maintaining a Buy rating. The adjustment ...
The competitive menin-inhibitor space chalked further data from Syndax Pharmaceuticals Inc., which disclosed positive top-line results from the pivotal phase II portion of the Augment-101 study, ...
While awaiting an FDA decision for its small molecule revumenib in one form of acute leukemia, Syndax Pharmaceuticals is trying to build a case for its candidate in another. Though the drug met ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback